AAAAAA
Results:
1-7
|
Results: 7
Authors:
Altarescu, G
Moore, DF
Pursley, R
Campia, U
Goldstein, S
Bryant, M
Panza, JA
Schiffmann, R
Citation: G. Altarescu et al., Enhanced endothelium-dependent vasodilation in Fabry disease, STROKE, 32(7), 2001, pp. 1559-1562
Authors:
Garvey, MA
Toro, C
Goldstein, S
Altarescu, G
Wiggs, EA
Hallett, M
Schiffmann, R
Citation: Ma. Garvey et al., Somatosensory evoked potentials as a marker of disease burden in type 3 Gaucher disease, NEUROLOGY, 56(3), 2001, pp. 391-394
Authors:
Altarescu, G
Hill, S
Wiggs, E
Jeffries, N
Kreps, C
Parker , CC
Brady, RO
Barton, NW
Schiffmann, R
Bannarjee, TK
Crutchfield, K
Frei, K
McKee, MA
Moore, DF
Tournay, A
Citation: G. Altarescu et al., The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease, J PEDIAT, 138(4), 2001, pp. 539-547
Authors:
Moore, DF
Scott, LTC
Gladwin, MT
Altarescu, G
Kaneski, C
Suzuki, K
Pease-Fye, M
Ferri, R
Brady, RO
Herscovitch, P
Schiffmann, R
Citation: Df. Moore et al., Regional cerebral hyperperfusion and nitric oxide pathway dysregulation inFabry disease - Reversal by enzyme replacement therapy, CIRCULATION, 104(13), 2001, pp. 1506-1512
Authors:
Altarescu, G
Schiffmann, R
Parker, CC
Moore, DF
Kreps, C
Brady, RO
Barton, NW
Citation: G. Altarescu et al., Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease, BL CELL M D, 26(4), 2000, pp. 285-290
Authors:
DeGraba, T
Azhar, S
Dignat-George, F
Brown, E
Boutiere, B
Altarescu, G
McCarron, R
Schiffmann, R
Citation: T. Degraba et al., Profile of endothelial and leukocyte activation in Fabry patients, ANN NEUROL, 47(2), 2000, pp. 229-233
Authors:
Syed, NA
Sandbrink, F
Luciano, CA
Altarescu, G
Weibel, T
Schiffmann, R
Floeter, MK
Citation: Na. Syed et al., Cutaneous silent periods in patients with Fabry disease, MUSCLE NERV, 23(8), 2000, pp. 1179-1186
Risultati:
1-7
|